The Australian medical community is abuzz with the emergence of retatrutide, a novel dual GIP and GLP-1 receptor showing remarkable results in early trials for addressing obesity. This medication suggests a https://dftsocial.com/story22907143/retatrutide-australia-australia-a-potential-hope-for-weight-management